Next generation cancer therapies targeting cancer networks

ended

"Pattern BioSciences is an ETH Zurich Spin-Off and an innovative biotechnology start up that proposes a paradigm shifting approach towards tailored and customizable cancer therapies. The company is commercializing the disruptive ""Network against Network"" approach to cancer therapies, which takes into account tumor complexity and probes and targets tumor cells at multiple points of tumor molecular network. The therapies will be more efficacious, less toxic and less prone to drug resistance compared to the state of the art treatments. Building on large IP portfolio and extensive expertise and know-how of its founders, the company proposes this feasibility study to assess the commercialization potential of its offering via intensive partner search, stakeholder alignment, freedom to operate analysis, and formulating IPR and knowledge management strategy. With company's current Minimal Viable Product (MVP) at TRL 6, interaction with prospective parters during this feasibility study will define the set of Customizable Therapeutic Prototypes (CTPs) at TRL 9, conducive to entering into partnership deals. Delivering CTPs in the Phase II of the innovation action will enable the company to enter into large scale, long term partnership agreements with established players in Pharma and Biotech industries and execute a European-wide growth and expansion plan, creating multiple jobs and strengthening Europe as an innovative Biotechnology hub."